Key Points – Medtronic posted strong fiscal Q4 and full-year results, with revenue of $9.8 billion in the quarter and $36.4 billion for the year, both above expectations.
Management said it was the company’s strongest top-line performance in a decade, driven by growth across cardiac ablation, diabetes, medical-surgical, and neuroscience businesses. – Cardiac ablation was the standout growth engine, as Cardiac Ablation Solutions surged 78% worldwide and pulsed field ablation jumped 145% globally
Medtronic said its CAS business is now annualizing at more than $2 billion and expects continued outgrowth versus the broader market in fiscal 2027. – The company guided for continued growth in fiscal 2027, forecasting organic revenue growth of 6.75% to 7.25% and adjusted EPS of $5.90 to $6.00. The outlook includes the newly separated MiniMed diabetes business and factors in an expected $250 million tariff hit to cost of goods sold. – 3 Reasons Analysts Love DexCom Medtronic (NYSE:MDT) reported what executives described as its strongest top-line performance in a decade, as growth in cardiac ablation, diabetes, medical-surgical products and select neuroscience platforms helped drive fiscal fourth-quarter and full-year results above expectations. Chairman and Chief Executive Officer Geoff Martha said the company generated $9.8 billion in revenue in the fourth quarter of fiscal 2026, up 9.9% on a reported basis and 6.6% organically.
For the full fiscal year, revenue was $36.4 billion, up 8.4% reported and 5.8% organically. Adjusted earnings per share were $1.55 for the quarter and $5.53 for the year. – Intuitive Surgical’s Selloff Sets Up a 30% Rebound Opportunity “These results represent the compounding impact of deliberate choices we’ve made across strategy, operations, and culture,” Martha said, citing execution in foundational businesses such as cardiac rhythm management, cranial and spinal technologies, and surgical products, as well as progress in higher-growth…